Has Ali Sajjad, MD received payments from drug or device companies?

Yes. Drug and device makers reported $87,224 in general payments to Ali Sajjad, MD across 89 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ali Sajjad, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ali Sajjad, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ali Sajjad, MD

Rheumatology · Maplewood, MNNPI 1619913621

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $65,469 of the $87,224 with a category attached, or 75.1%. Bristol Myers Squibb accounts for 74.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $72,478 and has fallen 92.5% since, to $5,425 in 2022. Among rheumatology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,224in general payments, 2019–2025

Across 89 payments — averaging $980.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bristol Myers Squibb$65K
Amgen$17K
Novartis$6K

What the payments were for

Consulting fees$4,9356%
Speaking & faculty fees$65,46975%
Travel & lodging$14,97217%
Food & beverage$1,8482%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bristol Myers Squibb	64	$64,570
Amgen	20	$16,873
Novartis	5	$5,781

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Otezla$77,982
COSENTYX$4,839
ILARIS$942

How this compares

$87,224 in reported general payments places this provider in the 95th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$117,193

Medicare patients

281

Services billed

3,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	118	$798,466
Enbrel SureclickEtanercept	63	$459,772
Humira PenAdalimumab	54	$368,097
OtezlaApremilast	47	$291,272
Orencia ClickjectAbatacept	33	$187,264
Cimzia (2 Pack)Certolizumab Pegol	25	$144,820
Xeljanz XrTofacitinib Citrate	22	$128,753
Taltz AutoinjectorIxekizumab	13	$91,990
Enbrel MiniEtanercept	12	$84,510
HumiraAdalimumab	12	$76,110
Hydroxychloroquine Sulfate	670	$32,396
MethotrexateMethotrexate Sodium	846	$25,316
Leflunomide	256	$17,107
Duloxetine Hcl	361	$9,077
Sulfasalazine DrSulfasalazine	123	$6,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenOtezla	$16,873	$291,27247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Maplewood

Asim KhanMaple Grove$1.2M
Parastoo FazeliMinneapolis$149K
Robert TierneySt Louis Park$137K
Steven YtterbergRochester$87K
Cornelia WeyandRochester$59K
Eric MattesonRochester$51K
Jeffrey WilsonEdina$49K
John DavisRochester$32K
David RidleyEagan$26K
Ashima MakolRochester$23K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →